| 000 | 01562 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250513173836.0 | ||
| 264 | 0 | _c19951129 | |
| 008 | 199511s 0 0 eng d | ||
| 022 | _a1170-7690 | ||
| 024 | 7 |
_a10.2165/00019053-199400062-00007 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSouêtre, E | |
| 245 | 0 | 0 |
_aEconomic analysis of lenograstim in the correction of neutropenia following chemotherapy for non-Hodgkin's lymphoma. _h[electronic resource] |
| 260 |
_bPharmacoEconomics _c1994 |
||
| 300 |
_a36-43 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdjuvants, Immunologic _xeconomics |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 | _aChemotherapy, Adjuvant |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFrance |
| 650 | 0 | 4 |
_aGranulocyte Colony-Stimulating Factor _xeconomics |
| 650 | 0 | 4 |
_aHospitalization _xeconomics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLenograstim |
| 650 | 0 | 4 |
_aLymphoma, Non-Hodgkin _xcomplications |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeutropenia _xchemically induced |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aRecombinant Proteins _xeconomics |
| 700 | 1 | _aQing, W | |
| 773 | 0 |
_tPharmacoEconomics _gvol. 6 Suppl 2 _gp. 36-43 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2165/00019053-199400062-00007 _zAvailable from publisher's website |
| 999 |
_c10131971 _d10131971 |
||